Market revenue in 2023 | USD 77.8 million |
Market revenue in 2030 | USD 174.7 million |
Growth rate | 12.3% (CAGR from 2023 to 2030) |
Largest segment | Breast cancer |
Fastest growing segment | Breast Cancer |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Breast Cancer |
Key market players worldwide | Thermo Fisher Scientific Inc, AbbVie Inc, Merck KGaA, Lonza Group Ltd, Bionomics Ltd ADR, Menarini Group, Miltenyi Biotec, PromoCell GmbH, Macrogenics Inc, FUJIFILM Holdings Corp, Stemcell Holdings Inc Ordinary Shares, Sino Biological, Lineage Logistics, Mereo BioPharma Group PLC ADR |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cancer stem cells market will help companies and investors design strategic landscapes.
Breast cancer was the largest segment with a revenue share of 100% in 2023. Horizon Databook has segmented the Latin America cancer stem cells market based on breast cancer covering the revenue growth of each sub-segment from 2018 to 2030.
Horizon Databook provides a detailed overview of continent-level data and insights on the Latin America cancer stem cells market , including forecasts for subscribers. This continent databook contains high-level insights into Latin America cancer stem cells market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account